SABCS 2022 | Emerging immunotherapy beyond checkpoint inhibitors for TNBC

Yara Abdou, MD, UNC School of Medicine, Chapel Hill, NC, discusses emerging immunotherapy beyond immune checkpoint inhibitors (ICIs) for triple-negative breast cancer (TNBC). Currently, the only approved immunotherapeutic approach for TNBC consists of ICIs, particularly pembrolizumab used in combination with chemotherapy for the treatment of patients with metastatic TNBC that expressed PD-L1, as well as in the neoadjuvant and adjuvant setting for high-risk early-stage TNBC in combination with chemotherapy. However, there are approximately 800 novel agents being actively developed for use in breast cancer and TNBC currently in various developmental stages. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.